CN101883786A - 人源化的notch融合蛋白组合物及治疗方法 - Google Patents

人源化的notch融合蛋白组合物及治疗方法 Download PDF

Info

Publication number
CN101883786A
CN101883786A CN2008801120573A CN200880112057A CN101883786A CN 101883786 A CN101883786 A CN 101883786A CN 2008801120573 A CN2008801120573 A CN 2008801120573A CN 200880112057 A CN200880112057 A CN 200880112057A CN 101883786 A CN101883786 A CN 101883786A
Authority
CN
China
Prior art keywords
fusion rotein
sequence
seq
patient
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801120573A
Other languages
English (en)
Chinese (zh)
Inventor
简·奇塔杰瓦斯基
嘉莉·夏伯尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of CN101883786A publication Critical patent/CN101883786A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
CN2008801120573A 2007-08-23 2008-08-22 人源化的notch融合蛋白组合物及治疗方法 Pending CN101883786A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96605207P 2007-08-23 2007-08-23
US60/966,052 2007-08-23
PCT/US2008/010045 WO2009025867A2 (en) 2007-08-23 2008-08-22 Compositions of humanized notch fusion proteins and methods of treatment

Publications (1)

Publication Number Publication Date
CN101883786A true CN101883786A (zh) 2010-11-10

Family

ID=40378882

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801120573A Pending CN101883786A (zh) 2007-08-23 2008-08-22 人源化的notch融合蛋白组合物及治疗方法

Country Status (15)

Country Link
US (2) US9127085B2 (https=)
EP (1) EP2193143B1 (https=)
JP (2) JP2010536855A (https=)
KR (1) KR20100076947A (https=)
CN (1) CN101883786A (https=)
AU (1) AU2008289462B2 (https=)
BR (1) BRPI0815291A2 (https=)
CA (1) CA2697262A1 (https=)
IL (2) IL204111A (https=)
MX (1) MX2010002053A (https=)
NZ (3) NZ600171A (https=)
RU (1) RU2532830C2 (https=)
SG (1) SG183763A1 (https=)
WO (1) WO2009025867A2 (https=)
ZA (1) ZA201001427B (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103917247A (zh) * 2011-10-04 2014-07-09 纽约哥伦比亚大学理事会 人类notch1引诱物
CN104870476A (zh) * 2012-11-21 2015-08-26 药物抗体公司 靶向vegfr-2和dll4的双靶向抗体及包含它的药物组合物
CN108707628A (zh) * 2018-05-28 2018-10-26 上海海洋大学 斑马鱼notch2基因突变体的制备方法
CN108753833A (zh) * 2018-05-28 2018-11-06 上海海洋大学 斑马鱼notch3基因突变体的制备方法
CN109467598A (zh) * 2018-11-28 2019-03-15 生命谷（海南）生物科技股份有限公司 肿瘤相关基因notch1突变短肽及其应用
CN110753552A (zh) * 2017-06-19 2020-02-04 细胞设计实验室股份有限公司 用于降低嵌合Notch受体的免疫原性的方法和组合物
CN115584341A (zh) * 2022-11-07 2023-01-10 浙江大学 一种鱼成肌细胞分化培养基及人造鱼肉组织方法
CN116790603A (zh) * 2023-08-18 2023-09-22 成都中科奥格生物科技有限公司 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途
US12617825B2 (en) 2022-04-08 2026-05-05 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
WO2011053822A2 (en) 2009-11-01 2011-05-05 The Brigham And Women's Hospital, Inc. Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
WO2007103114A2 (en) 2006-03-07 2007-09-13 The Brigham & Women's Hospital, Inc. Notch inhibition in the treatment or prevention of atherosclerosis
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2009103637A1 (en) * 2008-02-22 2009-08-27 Vrije Universiteit Brussel Method for generating islet beta cells from dedifferentiated exocrine pancreatic cells
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
WO2010021729A2 (en) 2008-08-22 2010-02-25 The Trustees Of Columbia University In The City Of New York Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
EP2970468B1 (en) 2013-03-13 2021-07-07 Novartis AG Notch2 binding molecules for treating respiratory diseases
WO2014151950A1 (en) * 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Notch1 decoy antagonists protect from obesity-induced insulin resistance and fatty liver
US20160030513A1 (en) * 2013-03-15 2016-02-04 The Trustees Of Columbia University In The City Of New York Notch1 Decoy Antagonists Protect From Obesity-Induced Insulin Resistance and Fatty Liver
CA2979759C (en) * 2015-04-16 2023-08-08 Eisai R&D Management Co., Ltd. Anti-human notch4 antibody
WO2017205651A1 (en) * 2016-05-25 2017-11-30 The Trustees Of Columbia University In The City Of New York Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling
US12065479B2 (en) 2017-11-16 2024-08-20 The Regents Of The University Of California Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof
WO2021202381A2 (en) * 2020-03-30 2021-10-07 Memorial Sloan Kettering Cancer Center Methods and compositions for modulating lipid storage in adipose tissue
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
CN114062682A (zh) * 2021-11-10 2022-02-18 厦门大学附属心血管病医院 Notch3作为检测靶标的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082651A1 (en) * 2000-09-22 2003-05-01 Genentech, Inc. Notch receptor agonists and uses
WO2003087159A2 (en) * 2002-04-05 2003-10-23 Lorantis Limited Modulators of the notch signalling pathway and uses thereof in medical treatment
WO2004024764A1 (en) * 2002-09-10 2004-03-25 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
US20060002924A1 (en) * 2002-08-03 2006-01-05 Bodmer Mark W Conjugate of notch signalling pathway modulators and their use in medical treatment
US20060030694A1 (en) * 2004-04-29 2006-02-09 Jan Kitajewski Notch-based fusion proteins and uses thereof
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US20070104746A1 (en) * 2005-07-29 2007-05-10 Seishiro Fujii Methods and compositions for reducing skin damage

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
FR2751986B1 (fr) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
GB9623236D0 (en) * 1996-11-07 1997-01-08 Imperial College Notch
US6379925B1 (en) * 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
WO2003042246A2 (en) 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
WO2006047878A1 (en) 2004-11-03 2006-05-11 British Columbia Cancer Agency Branch Cancer therapeutics and methods for their use
RU2461569C2 (ru) 2006-10-19 2012-09-20 Дженентек, Инк. Агонистические антитела против notch3 и их применение для лечения notch3-ассоциированных заболеваний
WO2010021729A2 (en) 2008-08-22 2010-02-25 The Trustees Of Columbia University In The City Of New York Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
TW201329105A (zh) * 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082651A1 (en) * 2000-09-22 2003-05-01 Genentech, Inc. Notch receptor agonists and uses
WO2003087159A2 (en) * 2002-04-05 2003-10-23 Lorantis Limited Modulators of the notch signalling pathway and uses thereof in medical treatment
US20060002924A1 (en) * 2002-08-03 2006-01-05 Bodmer Mark W Conjugate of notch signalling pathway modulators and their use in medical treatment
WO2004024764A1 (en) * 2002-09-10 2004-03-25 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
US20050261477A1 (en) * 2002-09-10 2005-11-24 Champion Brian R Pharmaceutical compositions and medical treatments comprising notch ligand proteins
US20060030694A1 (en) * 2004-04-29 2006-02-09 Jan Kitajewski Notch-based fusion proteins and uses thereof
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US20070104746A1 (en) * 2005-07-29 2007-05-10 Seishiro Fujii Methods and compositions for reducing skin damage

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103917247A (zh) * 2011-10-04 2014-07-09 纽约哥伦比亚大学理事会 人类notch1引诱物
CN104870476A (zh) * 2012-11-21 2015-08-26 药物抗体公司 靶向vegfr-2和dll4的双靶向抗体及包含它的药物组合物
CN104870476B (zh) * 2012-11-21 2018-04-13 药物抗体公司 靶向vegfr‑2和dll4的双靶向抗体及包含它的药物组合物
CN110753552A (zh) * 2017-06-19 2020-02-04 细胞设计实验室股份有限公司 用于降低嵌合Notch受体的免疫原性的方法和组合物
US12297243B2 (en) 2017-06-19 2025-05-13 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
CN110753552B (zh) * 2017-06-19 2024-03-19 细胞设计实验室股份有限公司 用于降低嵌合Notch受体的免疫原性的方法和组合物
CN108707628A (zh) * 2018-05-28 2018-10-26 上海海洋大学 斑马鱼notch2基因突变体的制备方法
CN108707628B (zh) * 2018-05-28 2021-11-23 上海海洋大学 斑马鱼notch2基因突变体的制备方法
CN108753833A (zh) * 2018-05-28 2018-11-06 上海海洋大学 斑马鱼notch3基因突变体的制备方法
CN109467598B (zh) * 2018-11-28 2021-11-09 生命谷（海南）生物科技股份有限公司 肿瘤相关基因notch1突变短肽及其应用
CN109467598A (zh) * 2018-11-28 2019-03-15 生命谷（海南）生物科技股份有限公司 肿瘤相关基因notch1突变短肽及其应用
US12617825B2 (en) 2022-04-08 2026-05-05 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
CN115584341A (zh) * 2022-11-07 2023-01-10 浙江大学 一种鱼成肌细胞分化培养基及人造鱼肉组织方法
CN116790603A (zh) * 2023-08-18 2023-09-22 成都中科奥格生物科技有限公司 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途
CN116790603B (zh) * 2023-08-18 2023-10-31 成都中科奥格生物科技有限公司 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途

Also Published As

Publication number Publication date
NZ618129A (en) 2015-05-29
ZA201001427B (en) 2011-05-25
IL204111A (en) 2015-08-31
CA2697262A1 (en) 2009-02-26
KR20100076947A (ko) 2010-07-06
US20160115217A1 (en) 2016-04-28
JP2016040245A (ja) 2016-03-24
EP2193143A4 (en) 2012-01-25
IL220723A0 (en) 2012-08-30
AU2008289462B2 (en) 2014-01-23
US9127085B2 (en) 2015-09-08
AU2008289462A1 (en) 2009-02-26
WO2009025867A2 (en) 2009-02-26
JP2010536855A (ja) 2010-12-02
NZ600171A (en) 2014-01-31
MX2010002053A (es) 2010-07-28
NZ583649A (en) 2012-06-29
RU2010110812A (ru) 2011-09-27
EP2193143B1 (en) 2016-06-08
WO2009025867A3 (en) 2009-12-30
EP2193143A2 (en) 2010-06-09
US20110008342A1 (en) 2011-01-13
BRPI0815291A2 (pt) 2015-02-03
RU2532830C2 (ru) 2014-11-10
SG183763A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
EP2193143B1 (en) Compositions of humanized notch fusion proteins and methods of treatment
JP2010536855A5 (https=)
US9475855B2 (en) Human Notch3 based fusion proteins as decoy inhibitors of Notch3 signaling
US8993725B2 (en) Notch-based fusion proteins and uses thereof
He et al. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis
CA2710082A1 (en) Methods for using and identifying modulators of delta-like 4
WO2008079326A2 (en) Methods for using and identifying modulators of delta-like 4
AU2012283924A1 (en) Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
CN113544150A (zh) 眼部病症中wnt信号传导的调节
KR101008785B1 (ko) 유사분열촉진 활성을 가진 Ｂｖ８ 핵산 및 폴리펩티드
JP2004506595A (ja) 血管形成及び心臓血管新生の促進又は阻害
Díaz-Coránguez et al. Blood-Retinal Barrier Development and Potential for Regeneration in Blinding Eye Disease
HK1151983B (en) Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
Wang Dissection of novel pathways leading to podocyte dysfunction and proteinuria

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101110